Globally, an estimated 170 million people are living with chronic hepatitis C infection. Most don't know it.
Approximately 3.5 million adults in the U.S. have chronic HCV infection.
More than 75 percent of them are people born from 1945 to 1965.
For nearly 30 years, Merck has been at the forefront of the response to chronic HCV, and our team continues to work tirelessly to advance scientific knowledge of this significant global public health issue.
Included more than 135 Clinical Trials in
Approximately 40 Countries
Drs. Eirum Chaudhri and Eliav Barr have worked together at Merck for many years in drug discovery. Learn more about why they find working on chronic hepatitis C so exciting, and what it takes to innovate.